Scholarlink

Purpose <p>Cystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with ≥ 1 F508del allele during ETI therapy. The device’s suitability for home monitoring of therapy success was also assessed.</p> Methods <p>In a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One + at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.</p> Results <p>Significant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1–5 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.</p> Conclusion <p>Sleepiz One + reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月23日

查看全文
  • Sarah Dietz-Terjung,
  • Svenja Straßburg,
  • Christoph Schöbel,
  • Tim Schulte,
  • Paul Dietz,
  • Fatma Ezzahra Gahbiche,
  • Jose Ortiz,
  • Christian Taube,
  • Gerhard Weinreich,
  • Sivagurunathan Sutharsan,
  • Matthias Welsner

摘要

Purpose

Cystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with ≥ 1 F508del allele during ETI therapy. The device’s suitability for home monitoring of therapy success was also assessed.

Methods

In a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One + at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.

Results

Significant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1–5 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.

Conclusion

Sleepiz One + reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.